NURIX THERAPEUTICS INC (NRIX:NASDAQ)
$16.96 -0.02 (-0.1178%)
Analysed NURIX THERAPEUTICS INC (NRIX:NASDAQ) News Sources
This Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug
08-06-2026
yahoo.com
Stocks Rally as Buyers Return After AI-Led Selloff
08-06-2026
barchart.com
Roche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion
08-06-2026
wsj.com
Roche's $2.3 Billion Nurix Deal Sends Shares Moving
08-06-2026
yahoo.com
Roche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying
08-06-2026
yahoo.com
Broader Market Settles Higher as Chipmakers Rally
08-06-2026
barchart.com
Company News for Jun 9, 2026
09-06-2026
yahoo.com
Strength Seen in Nurix Therapeutics (NRIX): Can Its 6.8% Jump Turn into More Strength?
09-06-2026
yahoo.com
TG Therapeutics (TGTX) Soars 7.5%: Is Further Upside Left in the Stock?
11-06-2026
yahoo.com
Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy
11-06-2026
yahoo.com
What is the current price of NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The current price of NURIX THERAPEUTICS INC (NRIX:NASDAQ) is $16.96.
NURIX THERAPEUTICS INC (NRIX:NASDAQ) absolute price change since previous trading day?
The absolute price change of NURIX THERAPEUTICS INC (NRIX:NASDAQ) since the previous trading day is $-0.02.
NURIX THERAPEUTICS INC (NRIX:NASDAQ) percentage price change since previous trading day?
The percentage price change of NURIX THERAPEUTICS INC (NRIX:NASDAQ) since the previous trading day is -0.1178%.
What is the most recent average sentiment score for NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The most recent average sentiment score for NURIX THERAPEUTICS INC (NRIX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for NURIX THERAPEUTICS INC (NRIX:NASDAQ)?
The most recent sentiment for NURIX THERAPEUTICS INC (NRIX:NASDAQ) is .
SEC-8K** Filing Available For NURIX THERAPEUTICS INC (NRIX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.